购物车0
产品总数：60942
| 中文名称 |
Hydrochlorothiazide
|
|---|---|
| 中文别名 |
氢氯噻嗪;双氢氯噻嗪;双氢克尿噻;双氢氯噻秦;双氢氯消痰;6-氯-3,4-二氢-2H-1,2,4-苯并噻二嗪-7-磺酰胺-1,1-二氧化物;二氢氯噻;格列美脲;氢喹维林;氢氯噻;氢氯噻嗪 标准品;氢氯噻嗪标准品(JP);乳酸环丙沙星(双氢克尿酸);双氢克尿塞 标准品;双氢氯噻嗪 USP标准品;六氯-1,1二氧-1,2,3,4-4H-1,2,4-苯并噻二嗪-7-磺胺;双氢克尿塞;6-氯-7-磺酰胺-3,4-二氢-1,2,4-苯并噻二嗪-1,1-二氧化物
|
| 英文名称 |
Hydrochlorothiazide
|
| 英文别名 |
Hydrochlorothiazide;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide;3,4-Dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide;6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide;6-Chloro-3,4-dihydro-7-sulphamoyl-1,2,4-ben-zoth-iadi-azine1,1-dioxcide;6-chloro-7-sulfamoyl-3,4-dihydro-2h-1,2,4-benzothiadiazine;6-Chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide;6-chloro-7-sulfamoyl-3,4-dihydro-2h-1,2,4-benzothiadiazine-1,1-dioxide;HCTZ;Hydrochlorothiazide solution;6-Chloro-3,4-Dihydro-(2H)-1,2,4-Benzothiadiazine-7-Sulfonamide 1,1-Dioxide;3,4-Dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide;6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide;3,4-Dihydrochlorothiazide;Hypothiazide;Esidrix;Oretic;Servithiazid;Hydrosaluric;Hidrotiazida;Dichlotiazid;Hydrochlorthiazide;Hydrochlorothiazid;Hydrodiuretic;Thiuretic;Maschitt;Aquarills;Newtolide;Disalunil;Diclotride;Dichlotride;Megadiuril;Hypothiazid;Aquarius;Vetidrex;Idrotiazide;Esidrex;Hydril;Nefrix;Hidril;Drenol;Hidrochlortiazid;Chlorosulthiadil;Hydro-Diuril;Hydro-Aquil;Jen-Diril;Dihydrochlorothiazide;HydroDIURIL;Dihydrochlorothiazid;Dihydrochlorothiazidum;Urodiazin;Neoflumen;Hydroth
|
| Cas No. |
58-93-5
|
| 分子式 |
C7H8ClN3O4S2
|
| 分子量 |
297.74
|
| 包装储存 |
Powder -20°C 3 years；4°C 2 years
|
| 产品详情 |
Hydrochlorothiazide (HCTZ) 是一种口服有效的噻嗪类的利尿药，可抑制转化 TGF-β/Smad 信号通路。Hydrochlorothiazide 通过打开钙激活钾 (KCA) 通道具有直接的血管松弛作用。Hydrochlorothiazide 改善心脏功能，减少纤维化并具有降压作用。
|
|---|---|
| 生物活性 |
Hydrochlorothiazide (HCTZ), an orally active diuretic drug of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
|
| 性状 |
Solid
|
| 体外研究(In Vitro) |
Hydrochlorothiazide belongs to thiazide class of diuretics. It reduces blood volume by acting on the kidneys to reduce sodium (Na) reabsorption in the distal convoluted tubule. The major site of action in the nephron appears on an electroneutral Na-Cl co-transporter by competing for the chloride site on the transporter. By impairing Na transport in the distal convoluted tubule, hydrochlorothiazide induces a natriuresis and concomitant water loss. Thiazides increase the reabsorption of calcium in this segment in a manner unrelated to sodium transport. Additionally, by other mechanisms, Hydrochlorothiazide is believed to lower peripheral vascular resistance. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 体内研究(In Vivo) |
Hydrochlorothiazide (HCTZ; orally bygavage; 12.5 mg/kg/d; 8 weeks) has improved cardiac function, reduced cardiac interstitial fibrosis and collagen volume fraction, decreased expression of AT1, TGF-β and Smad2 in the cardiac tissues in adult male Sprague Dawley rats. In addition, hydrochlorothiazide reduces plasma angiotensin II and aldosterone levels. Furthermore, hydrochlorothiazide inhibits angiotensin II-induced TGF-β1 and Smad2 protein expression in the neonatal rat ventricular fibroblasts. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years；4°C 2 years
|
| ClinicalTrial |
|
| 参考文献 |
[1]. Duarte, J.D. and R.M. Cooper-DeHoff, Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther, 2010. 8(6): p. 793-802.[2]. Jinghong Luo, et al. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovasc Ther. 2017 Apr;35(2).
|
| 溶解度数据 |
In Vitro: DMSO : 50 mg/mL (167.93 mM; Need ultrasonic)配制储备液
|
|---|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
